ClinicalTrials.gg
RecruitingNCT06911294FITPREVUpdated Aug 5, 2025

Feasibility of Innovative Approaches for Personalized Cardiovascular Prevention

An interventional study of Polygenic Risk Score and Digital app and wearable device in Coronary Heart Disease, sponsored by Catholic University of the Sacred Heart. Recruiting at 7 sites in Italy. Open to participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Catholic University of the Sacred Heart · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Coronary Disease with a site in Italy — 10 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Italy.

Planned enrollment
28th of 37
120 · median 476
Started
2025
with 2 others
No phase
17 of 58
4 open now
Primary completion
2026-02
later than 3 of 12 live
Registered
56th of 58
by date
Lead sponsor
4 of 58
Catholic University of the Sacred Heart

Among the 58 studies in Coronary Disease with a site in Italy, this one is the 28th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 17 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 56th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

10 of the 58 studies in Coronary Disease with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 40 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Coronary Disease with a site in Italy, or all of them as a file.
02

Study summary

The goal of the FITPREV (Feasibility of InnovaTive approaches for personalized cardiovascular PREVention: randomized controlled pilot trial and multidisciplinary evaluation for National Health Service implementation) clinical trial is to study the feasibility of innovative approaches( Polygenic Risk Score and health smartwatch) for personalized primary preventive interventions in cardiovascular diseases (CVD). The main questions it aims to answer are:

  • Feasibility of a greater study.
  • Feasibility of the interventions in a realistic setting, such as the medical office of a General Practitioner.

Participants will be randomized in one of the four parallel arms:

  • standard of care;
  • genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS);
  • digital intervention with a wearable device and its app;
  • digital intervention and genetic testing

The primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.

Secondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.

Read the detailed description

This study aims to evaluate the feasibility and secondarily efficacy of disclosing cardiovascular genetic risk-in the setting of a general practitioner's office-in the promotion of healthier lifestyle behaviors.

The enrollment period will last 6 months, with each participant taking part in the study for 12. There are three key time points in the study, T0 or baseline (enrollment phase), T1 or disclosure visit after one month, T2 intermediate visit(after six months) and T3 or final visit at 12 months. At enrollment, participants will be classified into risk categories based on cardiovascular risk using the SCORE-2 or SCORE 2-OP tool. Individuals aged 40-69, without diabetes or congenital hypercolesterolemia, with a SCORE-2 between 2.5% and 10% and a diagnosys of metabolic syndrome according to the American Hearth Association Criteria will be enrolled.

Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes:

  • Completing a questionnaire on socioeconomic status, area of residence, and lifestyle, using the Life's Essential 8 tool. The questionnaire will cover smoking status, alcohol consumption, dietary pattern, sleep pattern, and physical activity. Participants will be classified into favorable, intermediate, or unfavorable individual lifestyle patterns according to the Life's Essential 8 score.
  • Blood analysis will be performed to evaluate the lipid profile, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.

At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group.

The questionnaire will be administered at T0, T2, and T3. Blood analysis and cardiovascular profile evaluation will be conducted at both T0 and T3.

Feasibility Questionnaire: Both participants and medical professionals will complete a questionnaire on the acceptability and feasibility of the intervention.

03

Conditions studied

  • Coronary Heart Disease

Keywords

  • coronary artery disease
  • Polygenic Risk Score
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-69 years;
  • 10 year cardiovascular risk score SCORE2 between 2.5% and 10%.
  • Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:

    • Central or abdominal obesity, measured by waist circumference (greater than 40 inches - 102 cm in men and 35 inches - 89 cm in women).
    • Elevated triglycerides: levels equal to or greater than 150 mg/dL or use of medication for hypertriglyceridemia.
    • Low HDL cholesterol levels (less than 40 mg/dL in men and less than 50 mg/dL in women) or use of cholesterol-lowering medication.
    • Elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or use of antihypertensive medication.
    • Elevated fasting blood glucose: ≥100 mg/dL or use of glucose-lowering medication.

Exclusion criteria

Exclusion Criteria:

  • Diabetes:
  • Familial hypercholesterolemia;
  • Previous cardiovascular events.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    No intervention - Standard of Care

    Participants will receive traditional lifestyle advices in order to reduce the risk.

  • Experimental
    Genetic testing - PRS

    Arm Description: Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.

    Behavioral: Polygenic Risk Score

  • Experimental
    Experimental: Digital intervention - app and wearable device

    Arm Description: Participants will receive an app and a wearable device for the evaluation of various parameters.

    Behavioral: Digital app and wearable device

  • Experimental
    Digital intervention and genetic testing - PRS

    Arm Description: Participants will receive both app and wearable device and PRS information

    Behavioral: Polygenic Risk Score · Behavioral: Digital app and wearable device

Interventions

  • BehavioralPolygenic Risk Score

    genetic test for the evaluation of cardiovascular risk

  • BehavioralDigital app and wearable device

    a wearable device connected with its app

06

What researchers measure

Primary outcomes

  1. Feasibility for the patients

    Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).

    Time frame: 1 year

  2. Feasibility for the General Practitioners

    Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).

    Time frame: 1 year

Secondary outcomes

  1. Change in the Lifestyle Category

    The lifestyle category will be measured using the Life's Essential 8 tool. A change will be considered achieved if there is a shift towards a more favorable lifestyle category.

    Time frame: 12 months

  2. Modification of the Lipid Profile

    We will evaluate whether there is a change in the lipid profile compared to the baseline value. The modification of the lipid profile can also be considered as an indicator of the modification of the cardiovascular risk profile measured with the SCORE 2 charts.

    Time frame: 12 months

07

Study locations

7 of 7 sites recruiting
  • Studio Antonaci
    Rome, Italy, Italy
    Recruiting
  • Studio Colletti
    Rome, Italy
    Recruiting
  • Studio Maggiori
    Rome, Italy
    Recruiting
  • Studio Mammucari
    Rome, Italy
    Recruiting
  • Studio Marra
    Rome, Italy
    Recruiting
  • Studio Paoletti
    Rome, Italy
    Recruiting
  • Studio Pasca
    Rome, Italy
    Recruiting
08

References and documents

Publications

  • Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, Rosamond W; American Heart Association. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022 Aug 2;146(5):e18-e43. doi: 10.1161/CIR.0000000000001078. Epub 2022 Jun 29. PubMed 35766027 ↗
  • Tona DM, Porcelli M, Di Pumpo M, Cuoco F, Cuoco MF, Terenzi L, Antonaci L, Maggiori E, Colletti R, Guiducci E, Mammucari M, Paoletti F, Pasca G, Marra GA, Carbone D, Pasciuto T, Sanna T, Liuzzo G, Franceschini E, Villarini A, Pocetta G, de Waure C, Boccia S, Pastorino R. Feasibility of integrating genetic risk and digital health tools for cardiovascular prevention: the FitPreV protocol. Front Public Health. 2026 May 29;14:1800961. doi: 10.3389/fpubh.2026.1800961. eCollection 2026. PubMed 42293583 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Feb 10, 2026
CompletionEst.
Sep 10, 2026
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911294
Responsible party
Roberta Pastorino (Principal Investigator, Catholic University of the Sacred Heart) — Principal investigator
First posted
Apr 4, 2025
Start date
Feb 10, 2025
Primary completion
Feb 10, 2026 (estimated)
Completion
Sep 10, 2026 (estimated)
Last update
Aug 5, 2025

Study contacts

Roberta Pastorino
Contact
roberta.pastorino@unicatt.it
+393495624174

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion